Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure? Authors' reply - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement
Journal Articles Alimentary Pharmacology & Therapeutics (Suppl) Year : 2023

Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure? Authors' reply

Abstract

No abstract available

Domains

Hépatology and Gastroenterology Pharmacology
Fichier principal
Vignette du fichier
2023_Buisson_Aliment-Pharmacol_Therapeutics.pdf (176.19 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive
Licence
Attribution

Sabine ROSSI  : Connect in order to contact the contributor

https://hal.inrae.fr/hal-04056456

Submitted on : Monday, April 3, 2023-3:02:09 PM

Last modification on : Tuesday, August 27, 2024-4:14:03 PM

Download

Dates and versions

hal-04056456 , version 1 (03-04-2023)

Licence

Attribution

Identifiers

Cite

Anthony Buisson. Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure? Authors' reply. Alimentary Pharmacology & Therapeutics (Suppl), 2023, 57 (6), pp.735-736. ⟨10.1111/apt.17405⟩. ⟨hal-04056456⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM PRES_CLERMONT M2ISH INRAE MICA-UNITES
32 View
24 Download

Altmetric

Share

More